FOLR2 and melanoma: Anti-FRβ CAR-T cells targeting TAM achieved the selective elimination of FRβ+ TAM in the TME, resulting in an enrichment of pro-inflammatory monocytes, influx of endogenous tumor-specific CD8+ T cells, delayed tumor progression, and prolonged survival in murine models of ovarian cancer, colon cancer, and melanoma [114].